Organization | Baylor Scott and White

Baylor Scott and White Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Dallas TX United States (1903)

Organization Overview

First Clinical Trial

2004

NCT00103766

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Baylor Scott and White | Baylor Scott and White Health | Baylor Scott and White Institute for Rehabilitation | O'Brien, Jeana D., MD, FACP, FCCP

Active Ingredients

Drugs in Phase 4 Trials (5)

fluarix (1 trial)

inactivated influenza vaccine (1 trial)

lidocaine (xylocaine) (1 trial)

nitrous oxide (1 trial)

oxygen (1 trial)

Drugs in Phase 3 Trials (3)

cefoxitin (mefoxin) (1 trial)

piperacillin (pipracil) (1 trial)

tazobactam (Zosyn) (1 trial)

Drugs in Other Trials (1)

alteplase (Activase) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Influenza, Human (Phase 4)

Pancreatic Diseases (Phase 3)

Pancreatic Neoplasms (Phase 3)

Urinary Incontinence, Stress (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 9